The existing therapy choices are limited, and they only work for the symptoms of APOL1 Mediated Kidney Diseases such as inflammation, excessive fluid volume, and hypertension. As a result, innovative and targeted therapies that can reduce APOL1 protein levels in the body are urgently needed. In persons with an APOL1-mediated disease, too much APOL1 produces nephropathic symptoms and, eventually, kidney failure.
According to a recent analysis published by Future Market Insights (FMI), the global APOL1 mediated kidney disease market was worth US$ 3.0 billion in 2020 and is expected to grow at a stable CAGR of over 4% over the next five years (2020-2030).
The leading clinical-stage biopharmaceutical companies are currently concentrating their efforts on developing next-generation targeted therapies for APOL1 Mediated Kidney Diseases, particularly chronic kidney disease. The potential but unmet opportunities for APOL1 treated renal disorders are enticing both established and emerging biopharmaceuticals to enter the targeted therapeutics arena.
In the future, this tendency is predicted to provide a competitive advantage and exclusive monopoly in the worldwide market.
For example, in 2018, AstraZeneca signed a $330 million licensing agreement with Ionis Pharmaceuticals, Inc., a clinical-stage Innovator Company focused on rare disease research. Investigational new antisense medicine (AZD2373) is one of the licensed therapeutics for APOL1-mediated chronic renal disorders.
The Market Study on APOL1 Mediated Kidney Diseases Highlights
- Chronic renal disorders account for more than 95 percent of all APOL1-mediated ailments, according to the findings of the market study. Over the predicted period, the rising prevalence of hypertension-related renal disorders would raise treatment needs.
- Over 3/4 of the worldwide market is accounted for by North America. • Pipeline medications under development are slated to be marketed in the United States, catapulting it as a highly valuable sector of the market due to the disease’s high prevalence among persons of African American heritage.
- Major players are concentrating their efforts on substantial research and development for APOL1-targeted therapy.
For more insights into the market, Request a Sample Copy
